Status:
RECRUITING
Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
Lead Sponsor:
Pfizer
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational prospective study with two years of follow-up, designed to evaluate the effectiveness of tofacitinib in patients with moderate to severe ulcerative colitis in French clinical ...
Detailed Description
TO FAst is a non-interventional study in France with primary objective to describe the clinical benefit of tofacitinib 1 year after its initiation for the treatment of moderate to severe UC in routine...
Eligibility Criteria
Inclusion
- Patients of 18 years old or above
- Patients with confirmed diagnosis of moderate to severe ulcerative colitis
- Patients for whom gastroenterologist decides to initiate treatment with tofacitinib as per the French SmPC
- Patients informed about the study procedures and receiving an information letter signed by the investigator
Exclusion
- Patients who have already received tofacitinib treatment before baseline
- Patients that fulfill any of the contrindications according to the latest version of the SmPC
Key Trial Info
Start Date :
December 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2025
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT04424303
Start Date
December 4 2020
End Date
December 15 2025
Last Update
November 17 2025
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique de l Europe
Amiens, France, 80090
2
Hopital Sud
Amiens, France, 80480
3
Hopital Jean Minjoz
Besançon, France, 25003
4
Hopital de La Cote de Nacre
Caen, France, 14027